Caravaca F, Cubero J J, Jimenez F, López J M, Aparicio A, Cid M C, Pizarro J L, Liso J, Santos I
Servicio Nefrología, Hospital Regional Universitario Infanta Cristina, Extremadura University, Badajoz, Spain.
Nephrol Dial Transplant. 1995;10(5):665-70.
To assess the effect of the different modes of calcitriol administration on PTH-ionized calcium relationship we conducted a prospective clinical trial in 33 patients on chronic haemodialysis with secondary hyperparathyroidism (four times upper normal limit intact PTH) who were randomly assigned, with stratification to PTH levels, to receive daily oral, intermittent oral, or intermittent intravenous calcitriol at the same dose of 0.045 micrograms/kg/weekly. PTH-iCa curves were generated by inducing hypo- or hypercalcaemia in sequential haemodialysis 1 week apart, before and after 10 weeks on treatment. All patients were dialysed against a dialysate calcium concentration of 2.5 mEq/l throughout the study period. After drop-outs, 26 patients completed the study: 11 on intravenous calcitriol (mean basal PTH +/- SD: 666 +/- 280 pg/ml), eight on intermittent oral calcitriol (mean basal PTH: 831 +/- 361), and seven on daily oral calcitriol (mean basal PTH: 719 +/- 280). Serum ionized calcium and phosphorus significantly increased in intravenous and daily oral groups after calcitriol treatment, but not in the intermittent oral group. Basal PTH did not significantly change in the three groups after 10 weeks on treatment. Maximal PTH significantly decreased in intravenous group (1449 +/- 660 versus 1122 +/- 691 pg/ml, P = 0.0085) and at the limit of statistical significance in the intermittent oral group (1701 +/- 774 versus 1445 +/- 634, P = 0.12), but it did not change in the daily oral group. Minimal PTH did not modify in the three groups. In all three groups, a shift to the right in the PTH-iCa relationships were observed, with significant changes in the set point of calcium.(ABSTRACT TRUNCATED AT 250 WORDS)
为评估不同方式给予骨化三醇对甲状旁腺激素-离子钙关系的影响,我们对33例慢性血液透析合并继发性甲状旁腺功能亢进(完整甲状旁腺激素水平高于正常上限四倍)的患者进行了一项前瞻性临床试验。这些患者根据甲状旁腺激素水平分层后,随机分组,接受相同剂量(0.045微克/千克/周)的每日口服、间歇口服或间歇静脉注射骨化三醇治疗。在治疗10周前后,通过在间隔1周的连续血液透析中诱导低钙血症或高钙血症,生成甲状旁腺激素-离子钙曲线。在整个研究期间,所有患者均使用钙浓度为2.5毫当量/升的透析液进行透析。剔除部分患者后,26例患者完成了研究:11例接受静脉注射骨化三醇(平均基础甲状旁腺激素±标准差:666±280皮克/毫升),8例接受间歇口服骨化三醇(平均基础甲状旁腺激素:831±361),7例接受每日口服骨化三醇(平均基础甲状旁腺激素:719±280)。骨化三醇治疗后,静脉注射组和每日口服组的血清离子钙和磷显著升高,而间歇口服组未升高。治疗10周后,三组的基础甲状旁腺激素均无显著变化。静脉注射组的最大甲状旁腺激素显著降低(1449±660对1122±691皮克/毫升,P = 0.0085),间歇口服组降至统计学意义临界值(1701±774对1445±634,P = 0.12),而每日口服组未变化。三组的最小甲状旁腺激素均未改变。在所有三组中,均观察到甲状旁腺激素-离子钙关系向右偏移,钙设定点有显著变化。(摘要截取自250词)